US Secretary of Health Robert F. Kennedy Jr. announces several regulatory changes that could expand access to peptides. These are substances that serve as the basic building blocks of protein and have become popular in wellness trends. In many circles, especially among the biohacking community, peptides are associated with faster recovery from injury and potential effects on body composition.
Kennedy has repeatedly personally supported these substances, highlighting his own positive experiences, while at the same time criticizing the Food and Drug Administration for its excessively restrictive approach. During a guest appearance on The Joe Rogan Experience, he hinted that the regulatory body could soon enable the wider availability of approximately 14 different peptides through domestic pharmacies that create customized preparations.
However, the concrete steps are not yet clear. Kennedy spoke about the possible measures, stating that decisions will depend on an evaluation of the scientific data on the safety and effectiveness of these compounds. Additional indicators indicate that regulatory changes are in the pipeline.
Namely, a group of specialty pharmacies launched a legal dispute over restrictions, but the proceedings were suspended after the agency announced plans to adopt final guidelines covering certain peptides.
According to the FDA’s official statements, the priority remains the safety of patients – ensuring access to approved therapies and, when they are not adequate, enabling preparations under special conditions, with medical supervision and respect for quality. Special emphasis is placed on avoiding products from unregulated sources that may pose risks.
‘One of the Biggest Medical Experiments’ in History
Supporters of the Make America Healthy Again Movement, including influencers who promote and sell popular peptides, as well as some pharmacists, reacted positively to Robert F. Kennedy Jr.’s statements. They believe significant regulatory changes could follow soon. However, some members of the public express concern.
Some pharmacists and doctors warn that easing the Food and Drug Administration’s rules could open the door for numerous health risks, primarily because of limited scientific evidence on the use of many peptides.
Peptides, which are most commonly administered by subcutaneous injection, include already approved therapies, such as insulin, as well as modern GLP-1 weight-regulating drugs, including Ozempic and Wegovy. Due to the high demand for personalized medicine and the success of these therapies, it is estimated that the global market could reach $100 billion in the next decade.
However, in alternative circles, substances with alphanumeric names, such as BPC-157 and CJC-1295, are promoted, although their effectiveness has not been clearly confirmed or officially approved. Despite this, some in the population, often skeptical of conventional medicine and large pharmaceutical companies, turn to these products through social networks or specialized clinics that are increasingly common.
Critics warn that the wider availability of undertested substances could have consequences. As Alec Ginsberg, a representative of one of the American pharmacies, pointed out, this scenario could represent “one“ of the biggest medical experiments, in which the users themselves would practically become subjects.
According to Kennedy, regulatory changes in 2023, mandated by Joe Biden, led to some peptides being included in the potentially risky substances category, limiting their production in specialized pharmacies. This move has caused additional polemics between advocates and critics of this treatment.
Skeptics particularly note the contradiction in the movement’s positions, noting the simultaneous rejection of scientifically supported therapies and the acceptance of insufficiently researched alternatives. As Eric Topol, a researcher in personalized medicine, notes, there is an irony in some individuals rejecting medical interventions proven effective in millions of people while simultaneously accepting therapies with limited evidence.
Compounders’ Push on Peptides
Efforts by individual therapy pharmacists to influence the regulatory framework have been ongoing for years, independent of the interest the Make America Healthy Again Movement has brought to the topic. In a lawsuit filed in 2024, industry representatives argued that the Food and Drug Administration, during the Joe Biden administration, used the changes to delay the implementation of clear definition rules for allowable compounding substances.
A special focus was on several peptides associated with different indications, which were classified as potentially risky. This classification has initiated a discussion about the extent to which existing regulatory criteria adequately balance the safety and availability of therapies.
On the other hand, the pharmaceutical industry points to the problem of insufficient efficacy claims. Eli Lilly has warned about potentially misleading promotions of the AOD-9604 peptide and highlighted the risk of misinforming patients without solid scientific evidence.
Regulatory challenges were highlighted by inspection findings that pointed to quality control problems – from unreported side effects related to GLP-1 therapies at Novo Nordisk, to omissions and microbiological contamination in compounding facilities. These findings further complicate the debate on the liberation of access to peptides.
In response to criticism, representatives state that measures have been implemented and internal standards improved, with an emphasis on a regulatory framework that would simultaneously ensure safety while enabling greater availability of personalized therapeutic options.
In parallel with the popularity of injectable therapies for body weight regulation, interest in a broader range of peptides has increased significantly. The success of GLP-1 drugs increased significantly. The success of GLP-1 drugs has opened up space for new expectations, so the question of what additional effects similar substances could have is being asked more and more often. Eventual decisions by the Food and Drug Administration that would allow greater availability of peptides could further accelerate this trend.
According to Alec Ginsberg, there is a real possibility that interest in peptides will follow the same path as GLP-1 therapy, which has become part of the wider consciousness in a relatively short time. This development is confirmed by Jessica Duncan, who notes that patients are inquiring about peptides that are not part of standard protocols. However, it emphasizes that any potential application must be considered, taking into account the patient’s specific needs and circumstances, rather than applying generalized approaches.
At the same time, experts warn that regulatory changes do not indicate the current availability of products on the market. The process of adjusting production – from formulations to substances to suitable quality for human use – can take a long time. It is that certain products appear before reasonable doubt about their origin and quality standards.
Attention is also focused on the way communication with consumers is handled. The question arises whether manufacturers and distributors will emphasize specific, scientifically supported claims or will rely on vague formulations about potential benefits, similar to the approach often seen in marketing.
The entry of established companies, such as Hims, could improve transparency and quality control compared to the existing unregulated market. Still, experts point out that a manufacturing standard does not automatically imply proven safety or efficacy – but rather represents a relative improvement over previously available, less controlled options.
